Ruti Aga Banned for Six Years: How a Forged Prescription Turned a Two-Year Case Into Career Death

The Athletics Integrity Unit (AIU) has handed Ethiopian marathon runner Ruti Aga a six-year ban. This is not the outcome of an ordinary doping case — it is the outcome of a case in which an athlete, trying to avoid a two-year sanction, produced a document that never existed. That document tripled her sentence. According to the AIU statement issued on Thursday, Aga's sample taken after a half marathon in China in March returned an adverse finding. She won that race. The substance detected was methylprednisolone. The arithmetic of the sanction is straightforward: two years for presence of a prohibited substance, plus four years for tampering — misleading statements and fabricated documentation during the investigation — for a total of six years. The ban is dated from 10 September, the same date her provisional suspension began. An important technical correction is necessary here, because the entire legal foundation of the case rests on it. Methylprednisolone has been described in several reports as a "prohibited steroid," which is factually inaccurate. It is not an anabolic steroid but a glucocorticoid — class S9 on the World Anti-Doping Agency (WADA) Prohibited List. S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. The direct implication: a medically justified knee injection is entirely legal out of competition, and becomes a violation only if residues are present in an in-competition sample. Because of that technical detail, Aga had a legitimate defence available. She said the injection was administered to treat a knee injury. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners. That explanation is both medically plausible and legally usable — provided it is backed by genuine medical records, a genuine doctor and correct timing. What actually happened was the opposite. The AIU investigation found that the prescription submitted belonged to a clinic that did not exist. The "doctor" who wrote it was a family member with no medical registration. Questioned, that person claimed to have used "an old prescription pad from a former workplace" — and the clinic named on the pad explicitly disowned the claim. Three independent verification links snapped at once: no clinic, no registered doctor, and a disowned pad. This is the central irony of the affair. Had Aga produced authentic medical documentation and explained the route of administration and its distance from competition, the case could plausibly have landed at the no-significant-fault end — a reprimand or a substantially reduced period — and no tampering charge would have arisen at all. Instead, the forged prescription destroyed the one defence that could actually have worked. The case is a demonstration that, in the anti-doping system, unverifiable paperwork is more dangerous than the substance itself. Look at the sanction architecture and it is standard, not exceptional. Two years for presence is consistent with a finding involving a Specified Substance where intent is not proven. Four years for tampering is the standard WADA Code penalty. Together they make six. One thing the arithmetic makes clear: the panel rejected the mitigation that normally reduces a presence sanction. In other words, the forged document was itself circumstantial evidence of an intent to conceal. Backdating the ban to 10 September is no relief. Time served under provisional suspension counts against the ban, so the athlete gains nothing in real terms — only the date on paper moves. It is a procedural convenience, not a reduction. In career terms, the sanction is close to a death sentence. Aga is 32. Six years on, she will be nearly 38. The depth of Ethiopian women's marathoning is such that even a 2:18–2:20 performer is not automatically selected for the national team. For a 38-year-old with a doping record, both return and selection are practically impossible. The 2028 Olympic cycle is closed to her entirely. It is also worth remembering that her sporting record is not erased. The 2026 Tokyo Marathon title, and three second-place finishes at World Marathon Majors, are the credentials of a genuinely elite marathoner. The violation is anchored to a March race in a later year; the AIU statement does not say earlier results were annulled. Standard practice is that the result and prize money from the competition where the sample was collected are automatically voided, along with ranking points accrued after that date. So the March title, its prize money and subsequent points are very likely gone, while the 2026 title survives on paper. But a title that survives on paper does not survive commercially. Sponsorship in distance running is already thin, and after a doping ban an athlete becomes radioactive to brands. Historical prestige on one side, commercial zero on the other — that split is the permanent outcome of this case. The real root of the affair is not performance but a failure of medical governance. A knee injury was cited, and that is a recognised load-bearing problem in marathoners. Injured runners face pressure to mask pain in order to protect appearance-fee income; glucocorticoids are the cheapest and most available tool for that; and the medical network around these runners is often informal. A family member writing a prescription as a "doctor" is not a filing error — it is the signature of a system in which a credentialed team physician simply does not exist. And where there is no credentialed physician, there is no therapeutic-use-exemption (TUE) infrastructure either. A properly managed athlete would either hold or apply for a TUE, or observe WADA's route-specific washout period. Neither happened here — and that absence is precisely what opened the path to a forged prescription. The geographic and structural context matters too. The March race in China was almost certainly a World Athletics Label road race, with an elite women's field and AIU testing. For East African marathoners, Asia's label-race circuit has long been a lucrative, low-risk income tier between Majors. That same tier is now the AIU's highest-yield testing ground — the appearance-fee economy and the testing economy are colliding in the same races. The competitive picture is barely affected. Ethiopia's women's marathon has world-record-level depth; the removal of a 32-year-old with no global championship medals changes nothing in selection arithmetic. Kenya and Ethiopia are both structurally deep and both structurally exposed to entourage-level governance failure. The real shift is on enforcement. The cluster of AIU road-racing cases involving tampering forms a recognisable family: an initial substance violation, then a fabricated or altered explanation to cover it. It suggests the enforcement frontier has moved from detection to document verification. That is why the four-year tampering sanction here came not from a document alone but from statements made under questioning — meaning the conditions, language and translation of investigative interviews can themselves become contested. An appeal is open but of low value. A CAS appeal is typically possible within about 21 days of the reasoned decision. Overturning a document-based forgery finding is hard, however, because it rests not on one statement but on three independent verification failures. There is also a larger question of proportionality. A six-year ban has been imposed for a substance with no proven endurance benefit. The outcome will be cited two ways at once — as evidence of AIU rigour, and as evidence of disproportionate enforcement against African road runners. On the technical facts, both sides have arguments. One further point deserves emphasis: document forgery carries criminal exposure in itself, but the AIU's jurisdiction does not extend that far. The statement says nothing about whether the matter was referred to national authorities. Nor is any official response from the Ethiopian federation quoted. The conclusion is clear. In trying to avoid two years, Ruti Aga bought six. She had a legitimate medical defence and replaced it with forged paper. It was not the substance that ended her career; it was the document. And the case is a reminder that in the East African road-racing appearance-fee economy, the biggest vulnerability is not doping but the absence of credentialed medical support — because where there is no real doctor, someone willing to write a fake prescription is never far away.